• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Ependymoma - Pipeline Review, H2 2012 Product Image

Ependymoma - Pipeline Review, H2 2012

  • Published: December 2012
  • 52 pages
  • Global Markets Direct

Ependymoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Ependymoma - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ependymoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ependymoma. Ependymoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ependymoma.
- A review of the Ependymoma products under development by companies and universities/research institutes based on information derived from company READ MORE >

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Ependymoma Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Ependymoma 8
Ependymoma Therapeutics under Development by Companies 10
Ependymoma Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Ependymoma Therapeutics – Products under Development by Companies 16
Ependymoma Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Ependymoma Therapeutics Development 18
Astellas Pharma Inc. 18
Ependymoma – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
Temozolomide + Lapatinib - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
etoposide - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Temozolomide + Etoposide - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Bevacizumab + Camptosar - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
bevacizumab + [lapatinib ditosylate] - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Temozolomide + Lapatinib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Cisplatin + Etoposide - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Cisplatin + Etoposide - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
verteporfin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Vincristine + Carboplatin + Cyclophosphamide + Etoposide + G-CSF + Radiation Therapy - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 35
Dendritic cells + Imiquimod - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Carboplatin + Radiation Therapy - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
erlotinib hydrochloride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Temozolomide + Etoposide + Trofosfamid - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Sirolimus + Celecoxib + Etoposide + Cyclophosphamide - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
bevacizumab + [carboplatin] - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Cisplatin + Cyclophosphamide + Etoposide + Vincristine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Ependymoma Therapeutics – Drug Profile Updates 48
Ependymoma Therapeutics - Dormant Products 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Number of Products Under Development for Ependymoma, H2 2012 8
Products under Development for Ependymoma – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Astellas Pharma Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Ependymoma Therapeutics – Drug Profile Updates 48
Ependymoma Therapeutics – Dormant Products 50

List of Figures
Number of Products under Development for Ependymoma, H2 2012 8
Products under Development for Ependymoma – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos